Degenerative diseases such Diabetes Mellitus, and critical limb ischemia and neurodegenerative diseases such as Multiple Sclerosis, Parkinson's disease, and Alzheimer's are complex diseases that are growing world-wide at exponential rates. They are becoming the most common causes of death after cardiovascular disease.
Clinical and translational research initiatives are the key to advancing scientific progress. However, industry-sponsored clinical trials often only look for new medicines that can treat symptoms, but not the underlying causes. More often than not, these clinical trials only evaluate the viability of therapeutic agents that are selected by the organization that funds the research. By design, these clinical trials need to satisfy commercial interests with market expectations of profitability, which do not always coincide with patients’ needs.
Our research meets the definition of a growing a consensus of the definition of novel, independent research, which illustrates its value. We appeal to all stakeholders to support this type of research for the benefit of all patients.